Using its laboratory based at the University of Sussex campus, Centrix will act as a bridge between pioneering science and real-world medicines, combining Centrix’s formulation expertise with the University’s research strengths and talent pipeline.
Sharing expertise, equipment, and insight, both Centrix and the University of Sussex will enable the faster development of new therapies, ensuring promising molecules are transformed into robust, scalable drug products ready to improve patient lives.
Centrix, headquartered in Hove, East Sussex, is targeting revenue growth of 50% year-on-year during the next 2 years.
Supporting this ambition is an £850,000 investment in advanced equipment that enables high-quality formulation development while using minimal quantities of active pharmaceutical ingredients, a key advantage for biotech companies developing early-stage molecules.
Kate Thorpe, Head of Business Partnerships at the University of Sussex, said: “We’re proud to host Centrix at Sussex. Their presence brings real-world drug product innovation into our academic community and gives our students unique opportunities to engage with an R&D-led organisation."
"This collaboration is about more than facilities; it’s about combining academic insight with industry expertise to move new medicines closer to patients.”
Further building on its network of partners, Centrix has developed an Integrated Chemistry, Manufacturing & Control (CMC) Partnership that will strengthen the support it offers innovator biopharma companies.
The Partnership with Sai Life Sciences and Agility Life Sciences will involve all three working together to bring preclinical studies to first-in-human (FIH) trials quickly and efficiently.
Chris Davison, CEO of Custom Pharmaceuticals and Centrix Pharma Solutions, said: “Launching Centrix marks a bold new chapter for us. We’ve evolved from packaging to manufacturing, and now we’re stepping up as an innovation partner in drug product development."
“Being based at the University of Sussex allows us to spark collaboration, blending our know-how with academic research and the energy of future scientists. Together, we’re pushing forward the ideas that will shape tomorrow’s medicines.”
Custom Pharmaceuticals will continue to operate alongside Centrix, working with contract manufacturing organisations (CMOs) to produce high-quality pharmaceutical products from start to finish.
Centrix will focus on building collaborative pathways for drug product innovation, driving the next wave of therapies to market.